Englander Institute for Precision Medicine

Publications

Found 16 results
Author Title Type [ Year(Asc)]
Filters: Author is Spisek, Radek  [Clear All Filters]
2024
Kasikova L, Rakova J, Hensler M, Lanickova T, Tomankova J, Pasulka J, Drozenova J, Mojzisova K, Fialova A, Vosahlikova S et al..  2024.  Tertiary lymphoid structures and B cells determine clinically relevant T cell phenotypes in ovarian cancer.. Nat Commun. 15(1):2528.
Holicek P, Guilbaud E, Klapp V, Truxova I, Spisek R, Galluzzi L, Fucikova J.  2024.  Type I interferon and cancer.. Immunol Rev. 321(1):115-127.
2023
Holicek P, Truxova I, Rakova J, Salek C, Hensler M, Kovar M, Reinis M, Mikyskova R, Pasulka J, Vosahlikova S et al..  2023.  Type I interferon signaling in malignant blasts contributes to treatment efficacy in AML patients.. Cell Death Dis. 14(3):209.
2022
Fucikova J, Hensler M, Kasikova L, Lanickova T, Pasulka J, Rakova J, Drozenova J, Fredriksen T, Hraska M, Hrnciarova T et al..  2022.  An Autologous Dendritic Cell Vaccine Promotes Anticancer Immunity in Patients with Ovarian Cancer with Low Mutational Burden and Cold Tumors.. Clin Cancer Res. 28(14):3053-3065.
Fucikova J, Palova-Jelinkova L, Klapp V, Holicek P, Lanickova T, Kasikova L, Drozenova J, Cibula D, Álvarez-Abril B, García-Martínez E et al..  2022.  Immunological control of ovarian carcinoma by chemotherapy and targeted anticancer agents.. Trends Cancer. 8(5):426-444.
2021
Fucikova J, Spisek R, Kroemer G, Galluzzi L.  2021.  Calreticulin and cancer.. Cell Res. 31(1):5-16.
Cibula D, Rob L, Mallmann P, Knapp P, Klat J, Chovanec J, Minar L, Melichar B, Hein A, Kieszko D et al..  2021.  Dendritic cell-based immunotherapy (DCVAC/OvCa) combined with second-line chemotherapy in platinum-sensitive ovarian cancer (SOV02): A randomized, open-label, phase 2 trial.. Gynecol Oncol. 162(3):652-660.
Fucikova J, Coosemans A, Orsulic S, Cibula D, Vergote I, Galluzzi L, Spisek R.  2021.  Immunological configuration of ovarian carcinoma: features and impact on disease outcome.. J Immunother Cancer. 9(10)
Rakova J, Truxova I, Holicek P, Salek C, Hensler M, Kasikova L, Pasulka J, Holubova M, Kovar M, Lysak D et al..  2021.  TIM-3 levels correlate with enhanced NK cell cytotoxicity and improved clinical outcome in AML patients.. Oncoimmunology. 10(1):1889822.
2020
Truxova I, Kasikova L, Salek C, Hensler M, Lysak D, Holicek P, Bilkova P, Holubova M, Chen X, Mikyskova R et al..  2020.  Calreticulin exposure on malignant blasts correlates with improved natural killer cell-mediated cytotoxicity in acute myeloid leukemia patients.. Haematologica. 105(7):1868-1878.
Galluzzi L, Vitale I, Warren S, Adjemian S, Agostinis P, Martinez ABuqué, Chan TA, Coukos G, Demaria S, Deutsch E et al..  2020.  Consensus guidelines for the definition, detection and interpretation of immunogenic cell death.. J Immunother Cancer. 8(1)
Fucikova J, Kepp O, Kasikova L, Petroni G, Yamazaki T, Liu P, Zhao L, Spisek R, Kroemer G, Galluzzi L.  2020.  Detection of immunogenic cell death and its relevance for cancer therapy.. Cell Death Dis. 11(11):1013.
Buqué A, Bloy N, Perez-Lanzón M, Iribarren K, Humeau J, Pol JG, Levesque S, Mondragon L, Yamazaki T, Sato A et al..  2020.  Immunoprophylactic and immunotherapeutic control of hormone receptor-positive breast cancer.. Nat Commun. 11(1):3819.
Hensler M, Kasikova L, Fiser K, Rakova J, Skapa P, Laco J, Lanickova T, Pecen L, Truxova I, Vosahlikova S et al..  2020.  M2-like macrophages dictate clinically relevant immunosuppression in metastatic ovarian cancer.. J Immunother Cancer. 8(2)
Buqué A, Bloy N, Perez-Lanzón M, Iribarren K, Humeau J, Pol JG, Levesque S, Mondragon L, Yamazaki T, Sato A et al..  2020.  Publisher Correction: Immunoprophylactic and immunotherapeutic control of hormone receptor-positive breast cancer.. Nat Commun. 11(1):4787.
Vanmeerbeek I, Sprooten J, De Ruysscher D, Tejpar S, Vandenberghe P, Fucikova J, Spisek R, Zitvogel L, Kroemer G, Galluzzi L et al..  2020.  Trial watch: chemotherapy-induced immunogenic cell death in immuno-oncology.. Oncoimmunology. 9(1):1703449.